GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Perseus Proteomics Inc (TSE:4882) » Definitions » EV-to-EBITDA

Perseus Proteomics (TSE:4882) EV-to-EBITDA : -2.84 (As of May. 21, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Perseus Proteomics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Perseus Proteomics's enterprise value is 円2,585.77 Mil. Perseus Proteomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was 円-911.51 Mil. Therefore, Perseus Proteomics's EV-to-EBITDA for today is -2.84.

The historical rank and industry rank for Perseus Proteomics's EV-to-EBITDA or its related term are showing as below:

TSE:4882' s EV-to-EBITDA Range Over the Past 10 Years
Min: -25.14   Med: -2.77   Max: -0.28
Current: -2.83

During the past 6 years, the highest EV-to-EBITDA of Perseus Proteomics was -0.28. The lowest was -25.14. And the median was -2.77.

TSE:4882's EV-to-EBITDA is ranked worse than
100% of 711 companies
in the Drug Manufacturers industry
Industry Median: 14.89 vs TSE:4882: -2.83

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-21), Perseus Proteomics's stock price is 円356.00. Perseus Proteomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円-95.574. Therefore, Perseus Proteomics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Perseus Proteomics EV-to-EBITDA Historical Data

The historical data trend for Perseus Proteomics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perseus Proteomics EV-to-EBITDA Chart

Perseus Proteomics Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial - - - -3.57 -1.53

Perseus Proteomics Quarterly Data
Mar18 Mar19 Dec19 Mar20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.83 -1.53 -1.66 -4.33 -6.20

Competitive Comparison of Perseus Proteomics's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Perseus Proteomics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Perseus Proteomics's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Perseus Proteomics's EV-to-EBITDA falls into.



Perseus Proteomics EV-to-EBITDA Calculation

Perseus Proteomics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2585.765/-911.505
=-2.84

Perseus Proteomics's current Enterprise Value is 円2,585.77 Mil.
Perseus Proteomics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-911.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Perseus Proteomics  (TSE:4882) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Perseus Proteomics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=356.00/-95.574
=At Loss

Perseus Proteomics's share price for today is 円356.00.
Perseus Proteomics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-95.574.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Perseus Proteomics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Perseus Proteomics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Perseus Proteomics (TSE:4882) Business Description

Traded in Other Exchanges
N/A
Address
4-7-6, Komaba, Tokyo Park Building, Meguro-ku, Tokyo, JPN, 153-0041
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody based therapeutics and diagnostics drugs to cure against cancer and other diseases.

Perseus Proteomics (TSE:4882) Headlines

No Headlines